Brief: Plus Therapeutics Receives Medicare Enrollment Approval For Cnside Diagnostic
07/05/2026 12:33
May 7 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS RECEIVES MEDICARE ENROLLMENT APPROVAL FOR CNSIDE DIAGNOSTIC PLUS THERAPEUTICS INC - CNSIDE DIAGNOSTICS ENABLED TO SUBMIT CLAIMS FOR CNSIDE CSF ASSAY PLATFORM PLUS THERAPEUTICS INC - PAYMENT RATE FOR CPT CODE 0640U EFFECTIVE FOR BILLING JULY 1, 2026 Source text: ID:nGNX3QJYV0 Further company coverage: PSTV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer